- Investing.com
Inhaled Innovation | Explore MannKind's pioneering inhaled therapeutics, focusing on Tyvaso DPI and Afrezza, as the company navigates growth and challenges in specialized markets. |
Pipeline Potential | Delve into MannKind's promising pipeline, including NTM and IPF treatments, set to begin trials in June 2024, potentially reshaping the company's market position. |
Financial Trajectory | Learn about MannKind's robust 63% year-over-year revenue growth, driven by Tyvaso DPI, with 2024 revenue estimates increased to $266 million from $259.1 million. |
Market Outlook | Analyst price targets range from $5.00 to $6.50, reflecting optimism tempered by pipeline dependencies and interest expense concerns in a competitive landscape. |
Chỉ số cần so sánh | MNKD | Lĩnh vực Ngành- Số liệu trung bình từ một nhóm lớn các công ty Y Tế liên quan thuộc ngành | Mối quan hệ Mối quan hệMNKDCông TyLĩnh vực | |
---|---|---|---|---|
Tỉ số P/E | 50.2x | −0.5x | −0.6x | |
Tỷ Lệ PEG | 0.34 | 0.00 | 0.00 | |
Giá/G.Trị Sổ Sách | −29.9x | 1.0x | 2.6x | |
Giá / Doanh Số 12T | 5.5x | 10.3x | 3.3x | |
Tăng (Mục Tiêu của Nhà Phân Tích) | 86.2% | 199.0% | 37.0% | |
Giá Trị Hợp Lý Tăng | Mở Khóa | 11.9% | 4.6% | Mở Khóa |